Tursi, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 307
EU - Europa 248
AS - Asia 70
SA - Sud America 8
AF - Africa 1
Totale 634
Nazione #
US - Stati Uniti d'America 305
IT - Italia 77
SE - Svezia 51
IE - Irlanda 28
FR - Francia 25
SG - Singapore 25
CN - Cina 24
DE - Germania 23
UA - Ucraina 13
GB - Regno Unito 9
CO - Colombia 8
FI - Finlandia 7
IN - India 7
KR - Corea 6
RU - Federazione Russa 5
BE - Belgio 3
CZ - Repubblica Ceca 3
IL - Israele 2
IR - Iran 2
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CA - Canada 1
JP - Giappone 1
LI - Liechtenstein 1
NG - Nigeria 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
TR - Turchia 1
Totale 634
Città #
Chandler 97
Ashburn 30
Dublin 26
New York 22
Milan 20
Singapore 17
Marseille 13
Rome 12
Bogotá 8
Beijing 7
Princeton 7
Pune 7
Boardman 6
Boston 6
Jacksonville 6
Seoul 6
Fairfield 5
Houston 5
Helsinki 4
Redwood City 4
Seattle 4
Wilmington 4
Ann Arbor 3
Brussels 3
Chelsea 3
Los Angeles 3
Monte Argentario 3
Moscow 3
San Diego 3
San Mateo 3
Washington 3
Bremen 2
Brno 2
Busto Arsizio 2
Cattolica 2
Chicago 2
Edinburgh 2
Florence 2
Hangzhou 2
Jiaxing 2
Lawrence 2
Munich 2
Nanjing 2
Nuremberg 2
Paris 2
Pescara 2
Saint-Fons 2
Alexandria 1
Andover 1
Arezzo 1
Arzachena 1
Augusta 1
Belize City 1
Brdo 1
Bucharest 1
Capoliveri 1
Changsha 1
Chiswick 1
Cormeilles-en-Parisis 1
Dearborn 1
Frankfurt am Main 1
Gdansk 1
Grottaglie 1
Hebei 1
Huskvarna 1
Istanbul 1
Kaliningrad 1
Kish 1
Lagos 1
Lappeenranta 1
Las Vegas 1
Leawood 1
London 1
Massa 1
Montreal 1
Nanchang 1
Olongapo City 1
Santa Clara 1
Sofia 1
Tel Aviv 1
Tokyo 1
Torre del Lago Puccini 1
Trieste 1
University Park 1
Vaduz 1
Villongo 1
Woodbridge 1
Totale 415
Nome #
Effect of moderate and heavy alcohol consumption on intestinal transit time 82
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 76
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 59
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 58
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 52
Intestinal Microbiome Modulation During Coronavirus Disease 2019: Another Chance to Manage the Disease? 40
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care 35
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 34
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 34
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 31
Response to Jackson et al 31
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 25
Microbiota Composition in Diverticular Disease: Implications for Therapy 18
Microbiota Composition in Diverticular Disease: Implications for Therapy 16
When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach 13
SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease 12
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study 12
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 9
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 7
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis 6
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 5
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis 4
Totale 659
Categoria #
all - tutte 4.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.163


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202021 5 0 2 0 1 0 4 1 1 0 4 3
2020/202123 0 2 7 3 3 1 1 0 2 0 3 1
2021/202281 3 2 0 0 1 1 2 4 3 18 23 24
2022/2023237 27 27 11 40 13 25 16 26 19 10 16 7
2023/2024235 9 43 23 17 8 31 21 4 18 22 28 11
2024/202511 11 0 0 0 0 0 0 0 0 0 0 0
Totale 659